drugset / Trial / NCT06487715
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Phase 2
Unknown
42 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2025-03-01
- Completion
- 2026-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin-Bound Paclitaxel | Unknown | 260 mg/m2 | Other |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/m2 | Other |
| Subject | S-1 | Small molecule | 80 mg/m2 | Other |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Other |